Worth watching/speculative position; no price target.
Very well-written analysis. Have you seen the final change in primary endpoints submitted to clinicaltrials.gov on November 13? It's now both ADAS-Cog AND CDR-SB.
https://classic.clinicaltrials.gov/ct2/show/NCT04669028?term=biovie&draw=1&rank=5
Good comment, thank you.
Very well-written analysis. Have you seen the final change in primary endpoints submitted to clinicaltrials.gov on November 13? It's now both ADAS-Cog AND CDR-SB.
https://classic.clinicaltrials.gov/ct2/show/NCT04669028?term=biovie&draw=1&rank=5
Good comment, thank you.